KCNA3 and early-onset autosomal dominant Alzheimer disease: More recently, KV1.3 has been investigated as a target for inflammation in the central nervous system where KV1.3 expression has been described on activated, “M1-like” or disease-associated microglia in human brain or in rodent models of Alzheimer’s disease (Maezawa et al., 2018; Ramesha et al., 2021), multiple sclerosis (Rus et al., 2005), Parkinson’s disease (Sarkar et al., 2020), and ischemic stroke (Chen et al., 2018).